Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Study sponsor: DiaMedica Therapeutics Inc · DMAC
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-12Estimated
Enrollment · participants728Estimated
Source updated2026-09-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.